
NHS Foundation Trust

NXP800 versus cisplatin in ARID1a-mutated Ovarian Clear Cell Carcinoma xenograft models


James Stewart¹, Enrique Poradosu², Allison Woods², Shay Shemesh², Paul Clarke⁴, Robert Te Poele⁴, Paul Workman⁴, Susana Banerjee^{1,3} ¹ Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK, ² Nuvectis Pharma, Inc., 1 Bridge Plaza N., Fort Lee, NJ 07024, ³ Division of Clinical Studies, The Institute of Cancer Research, London, UK, ⁴ Centre for Cancer Research Drug Discovery and Division of Cancer Therapeutics at the Institute of Cancer Research, London, UK






HSF1 pathway inhibitors identified by the ability to block the induction of HSP72 by HSP90 inhibitor 17-AAG

- Discovered N,N'-4-methyl-1,3-phenylenediamide core structure
- Screen run in U2OS human osteosarcoma cells, followed up in SK-OV-3 human ovarian cancer cells
- Highly potent, low nanomolar hit against the HSF1 pathway and cancer cell growth inhibition
- Optimized through lead compound/chemical tool to clinical candidate^{1,2}
- NXP800 (CCT361814) has a clean profile across in vitro hERG, Cyp450, kinase and Cerep-Safety-87 assays



- Multiple cancer cell types treated with 5x GI50 NXP800 for 6 h and RNAseq profiled o significant enrichment of elevated integrated stress response (ISR) and ATF4-regulated genes
- immunoblotting confirmed induction of ISR and ATF4 0
- NanoString probeset confirmed elevated ISR/ATF4 and repressed HSF1 activity in vivo
- NXP800 treatment induces
- prolonged activation of the ISR³ • ISR activation blocks HSF1 activation
- Prolonged ISR/ATF4 activation and CHOP induction can result in cell death



Acknowledgements

NXP800 is licensed to Nuvectis Pharma


Contact

James Stewart, Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK, ames.Stewart@rmh.nhs.uk Enrique Poradosu, Nuvectis Pharma Inc., eporadosu@nuvectis.com

Lineage-specific sensitivity

NXP800 induces tumor regression in ARID1A mutated ovarian xenografts

Platinum sensitive⁴ (TOV21G) and resistant⁴ (SKOV3) xenografts were treated for 28 days with NXP800 (oral gavage, 35 mg/kg, 5 days on/2 days off) and cisplatin at the MTD⁵ (i.p. 4 mg/kg X 3). NXP800 achieved superior efficacy compared with cisplatin at the mice MTD, demonstrating substantial tumor regressions at a well tolerated dose/regimen, both in platinum resistant and sensitive ovarian cancer xenografts.



- the integrated stress response.
- NXP800 compared to cisplatin demonstrating substantial tumor regression.
- Phase 1a trial comprising a dose-escalation commenced and first patient treated in January 2022 (www.clinicaltrials.gov/ct2/show/NCT05226507).

References

- 1. Cheeseman MD et al. 2017. J. Med. Chem. 60:180. 2. Rye CS et al. 2016. Med. Chem. Comm. 2016 7:1580. 3. Pakos-Zebrucka K et al. 2016. EMBO Rep. 17:1374. 4. Ishiguro et al. 2016. J. Trans. Sci. 2(2):117-124.
- 5. Aston et al. 2017. BMC Cancer 17:684.

he Institute of Cancer Research



Summary

NXP800 is a first-in-class, orally active inhibitor of HSF1 activation, biomarkers indicate a mechanism of action involving activation of

Xenograft models of platinum sensitive and platinum resistant ovarian cancer with an ARID1A mutation show increased sensitivity to

• A phase 1b trial will evaluate NXP800 in patients with ARID1A mutated ovarian clear cell and endometrioid carcinoma.